Fresenius Kabi introduces Vasopressin Injection, USP, in US
Pharma Leaders
JUNE 15, 2023
Fresenius has invested nearly $1bn for the manufacture as well as distribution of Vasopressin to serve hospitals and health systems in the US. Bradycardia, tachyarrhythmias, decreased cardiac output, ischemia, and hyponatremia are some of the adverse reactions on using Vasopressin.
Let's personalize your content